Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK publishes Annual Report 2023

1 Mar 2024 12:15

RNS Number : 2981F
GSK PLC
01 March 2024
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2023

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2023 ('Annual Report 2023').

 

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2023 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2023 and the Notice of Annual General Meeting 2024 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 25 March 2024. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2023 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2023. The Annual Report 2023 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

1 March 2024

 

?

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAADFEFALEFA
Date   Source Headline
26th Sep 20225:09 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSGSK Chief Financial Officer succession
22nd Sep 20222:00 pmRNSUS FDA ODAC review of Zejula Phase III NOVA trial
22nd Sep 20227:00 amRNSGSK and Spero Therapeutics licence for tebipenem
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus
8th Sep 202212:58 pmRNSDirector/PDMR Shareholding
6th Sep 20221:00 pmRNSGSK provides update on FDA review of daprodustat
1st Sep 202211:48 amRNSTotal Voting Rights
24th Aug 20227:00 amRNSGSK Board changes
22nd Aug 20224:53 pmRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSFDA New Drug Application File Acceptance for MMB
17th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation update
16th Aug 20227:06 amRNSGSK completes acquisition of Affinivax, Inc.
12th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation
11th Aug 202211:51 amRNSDirector/PDMR Shareholding
10th Aug 20224:57 pmRNSDirector/PDMR Shareholding
1st Aug 20226:10 pmRNSTotal Voting Rights
1st Aug 20221:43 pmRNSDirector/PDMR Shareholding
29th Jul 20222:00 pmRNSDirector/PDMR Shareholding
29th Jul 202210:00 amRNSGSK Board change
28th Jul 20221:01 pmRNSDirector/PDMR Shareholding
27th Jul 20227:00 amRNS2nd Quarter Results
26th Jul 20225:35 pmRNSHolding(s) in Company
22nd Jul 20224:45 pmRNSHolding(s) in Company
22nd Jul 20224:17 pmRNSBoard and Committee Changes
19th Jul 20227:00 amRNSCompletion of GSK Share Consolidation
18th Jul 20226:00 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSHaleon demerger completion and share consolidation
12th Jul 20229:48 amRNSDirector/PDMR Shareholding
11th Jul 20225:30 pmRNSGSK
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.